ANGLE Signs a Contract with Eisai for Liquid Biopsy Diagnostic Solution
Shots:
- ANGLE has signed a contract with Eisai for the pilot study of worth $250,000
- As per the agreement, ANGLE will provide CTC analysis done by utilizing its Portrait HER2 assay for evaluating the HER2 status of breast cancer patients in a P-II study of BB-1701 (HER2 ADC)
- ANGLE's Portrait HER2 assay allows quantitative assessment of HER2 protein expression (using IF) and HER2/neu gene amplification (using FISH), aiding in identifying patients suitable for anti-HER2 ADC treatment
Ref: Polaris | Image: Eisai
Related News:- Bliss Biopharmaceutical Entered into a Clinical Trial Collaboration Agreement with Eisai for BB-1701 to Treat Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
